Holen Sie sich die Stockscreener-App
4.41
1.78%
-0.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAMP?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.49
Offen:
$4.45
24-Stunden-Volumen:
130.77K
Relative Volume:
0.58
Marktkapitalisierung:
$276.74M
Einnahmen:
$3.50M
Nettoeinkommen (Verlust:
$-80.40M
KGV:
-1.7152
EPS:
-2.5711
Netto-Cashflow:
$-29.83M
1W Leistung:
+6.27%
1M Leistung:
+6.01%
6M Leistung:
+8.09%
1J Leistung:
+197.97%
1-Tages-Spanne:
$4.331
$4.64
1-Wochen-Bereich:
$3.70
$4.64
52-Wochen-Spanne:
$1.46
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Firmenname
Camp 4 Therapeutics Corp
Sektor
Branche
Telefon
617-651-8867
Adresse
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.41 | 279.88M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-10-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-27 | Eingeleitet | Wedbush | Outperform |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
| 2022-08-16 | Hochstufung | Craig Hallum | Hold → Buy |
| 2021-12-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2021-09-24 | Bestätigt | Craig Hallum | Buy |
| 2021-06-25 | Bestätigt | Craig Hallum | Buy |
| 2020-12-18 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-05 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-01 | Bestätigt | Craig Hallum | Buy |
| 2019-03-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Hochstufung | Craig Hallum | Hold → Buy |
| 2018-12-14 | Bestätigt | B. Riley FBR | Buy |
| 2018-12-11 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Eingeleitet | Goldman | Neutral |
| 2018-10-15 | Eingeleitet | Jefferies | Hold |
| 2018-09-28 | Bestätigt | Craig Hallum | Hold |
| 2018-04-27 | Bestätigt | Craig Hallum | Hold |
| 2018-03-08 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-02-16 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
Alle ansehen
Camp 4 Therapeutics Corp Aktie (CAMP) Neueste Nachrichten
Balyasny Asset Management L.P. Reduces Stake in Camp4 Therapeuti - GuruFocus
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com Australia
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock - Investing.com
Camp4 Therapeutics (NASDAQ: CAMP) backer sees stake diluted after new share sales - Stock Titan
Camp4 Therapeutics (NASDAQ: CAMP) insider to sell 1,738 shares - Stock Titan
ETFs Investing in CAMP4 Therapeutics Corporation Stocks - TradingView
Analysts’ Top NA Picks: CAMP4 Therapeutics Corporation (CAMP), Wayfair (W) - The Globe and Mail
CAMP4 Therapeutics (CAMP) Jumps 8% to $4.86: Key Levels to WatchMomentum Stock Picks - vinanet.vn
Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates - scanx.trade
CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges - Stock Titan
CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028 - Stock Titan
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
Camp4 Therapeutics Corp SEC Filing (Aug 13, 2026) - Stock Titan
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Trails Edge reports 6% Camp4 Therapeutics stake (CAMP) totaling 3.79M shares - Stock Titan
CAMP4 Therapeutics Corp expected to post a loss of 21 cents a shareEarnings Preview - TradingView
CAMP Q1 2026 Earnings: EPS Miss Deepens 49.4% as Pre-Revenue Biotech Navigates Pipeline ProgressEarnings Surprise Stocks - Vinanet
Camp4 Therapeutics Corp CEO to launch new SYNGAP1 clinical trial in upcoming initiative - Traders Union
Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
CAMP4 Therapeutics (NASDAQ:CAMP) CEO Josh Mandel-Brehm Purchases 6,551 Shares - MarketBeat
Richard Young Buys 16,378 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
Insider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) CFO Buys $10,809.15 in Stock - MarketBeat
5AM Ventures group updates CAMP4 Therapeutics (CAMP) stake and warrant terms - Stock Titan
CAMP4 closes $50.1 million second tranche of private placement By Investing.com - Investing.com India
CAMP4 Therapeutics Secures $50 Million Private Financing - TipRanks
CAMP4 Therapeutics Closes Second Tranche of Private Placement, Raising $50.1 Million to Advance CMP-002 Development - Quiver Quantitative
Camp4 Therapeutics Raises $50.1 Million in Second Closing of Private Placement - TradingView
CAMP4 Therapeutics (Nasdaq: CAMP) raises $50.1M in second private placement closing - Stock Titan
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement - globenewswire.com
Camp4 Therapeutics Corp leverages regulatory RNA to target genetic root causes - Traders Union
CAMP4 Therapeutics (CAMP) Gains 3% as Stock Approaches Resistance at $3.54Time Weighted Price - vinanet.vn
CAMP4 Therapeutics Corporation Revenue Breakdown – NASDAQ:CAMP - TradingView
CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Forecasts - Yahoo! Finance Canada
Analysts Are Bullish on These NA Stocks: SpaceX (SPCX), CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
Camp4 Moves Into Human Trials -- The Upside Is Underpriced (NASDAQ:CAMP) - Seeking Alpha
CAMP4 receives Australian clearance for SYNGAP1 therapy trial By Investing.com - Investing.com UK
CAMP4 THERAPEUTICS CORPORATION (CAMP) stock price, news, quote and history - Yahoo Finance UK
Camp4 Therapeutics’ lead ASO approved for clinical trials in Australia - BioWorld News
CAMP4 receives Australian clearance for SYNGAP1 therapy trial - Investing.com Australia
Camp4 Therapeutics Corp secures clinical trial approval for first SYNGAP1 disease-modifying therapy in Australia - Traders Union
CAMP4 Therapeutics (CAMP) clears CMP-002 trial in Australia, eyes $50.1M raise - Stock Titan
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder - globenewswire.com
CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CAMP4 Therapeutics Corp (CAMP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CAMP|CAMP4 Therapeutics Corp|Price:3.440|Chg%:+0.280 - TradingKey
Camp4 Therapeutics secures TGA clearance for CMP-002, enabling up to $50.1M second closing - TradingView
CAMP|CAMP4 Therapeutics Corp|Price:3.160|Chg%:+0.150 - TradingKey
CAMP4 Therapeutics Corp (CAMP) Cash Flow - TradingKey
TradingKey - TradingKey
Finanzdaten der Camp 4 Therapeutics Corp-Aktie (CAMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Camp 4 Therapeutics Corp-Aktie (CAMP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 27 '26 |
Sale |
4.04 |
400,000 |
1,616,000 |
2,033,270 |
| Schwab Andrew J. | Director |
Aug 24 '26 |
Sale |
4.50 |
10 |
45 |
2,433,270 |
| Schwab Andrew J. | Director |
Aug 20 '26 |
Sale |
4.54 |
114,700 |
520,738 |
2,465,298 |
| Schwab Andrew J. | Director |
Aug 19 '26 |
Sale |
4.76 |
45,147 |
214,900 |
2,579,998 |
| Schwab Andrew J. | Director |
Aug 21 '26 |
Sale |
4.50 |
32,018 |
144,081 |
2,433,280 |
| Tardiff Daniel | Chief Scientific Officer |
Aug 19 '26 |
Sale |
4.76 |
1,738 |
8,273 |
0 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):